Premature Ejaculation - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 66 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Premature Ejaculation - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Premature Ejaculation - Pipeline Review, H2 2014', provides an overview of the Premature Ejaculation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premature Ejaculation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Ejaculation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Premature Ejaculation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Premature Ejaculation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Premature Ejaculation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Premature Ejaculation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Premature Ejaculation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Premature Ejaculation Overview 7
Therapeutics Development 8
Pipeline Products for Premature Ejaculation - Overview 8
Pipeline Products for Premature Ejaculation - Comparative Analysis 9
Premature Ejaculation - Therapeutics under Development by Companies 10
Premature Ejaculation - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Premature Ejaculation - Products under Development by Companies 15
Premature Ejaculation - Companies Involved in Therapeutics Development 16
Allergan, Inc. 16
SK Chemicals Co., Ltd. 17
Yungjin Pharm Ind. Co., Ltd. 18
Plethora Solutions Holdings plc 19
NeuroHealing Pharmaceuticals Inc. 20
Furiex Pharmaceuticals, Inc. 21
Dong-A Socio Group 22
Premature Ejaculation - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
tramadol hydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
(lidocaine + prilocaine) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
dapoxetine hydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
tramadol hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
onabotulinumtoxin A - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
DA-8031 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
IX-01 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
modafinil - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NCE-405 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
YPE-1706 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Premature Ejaculation - Recent Pipeline Updates 50
Premature Ejaculation - Dormant Projects 57
Premature Ejaculation - Discontinued Products 58
Premature Ejaculation - Product Development Milestones 59
Featured News & Press Releases 59
May 15, 2014: Innovus Pharma Announces the Beginning of Patient Enrollment in Its Post-Marketing EjectDelay Clinical Study in the Middle East 59
Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment 59
Mar 11, 2014: Plethora Solutions Provides Company update 60
Dec 06, 2013: Innovus Pharma Receives Product License Approval of EjectDelay for Premature Ejaculation From Health Canada 61
Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation 61
Oct 31, 2013: Furiex Pharmaceuticals Announces Priligy Launch in the United Kingdom by Menarini 62
Oct 29, 2013: Innovus Pharma Files Its Product License Application for Commercialization of EjectDelay for Premature Ejaculation in Canada 62
Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation 62
Jul 01, 2013: AGM Statement & PSD502 Regulatory Update 63
Jun 03, 2013: Ampio Pharma Provides Update On Sexual Dysfunction Portfolio 64
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 66
Disclaimer 66

List of Tables
Number of Products under Development for Premature Ejaculation, H2 2014 8
Number of Products under Development for Premature Ejaculation - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Premature Ejaculation - Pipeline by Allergan, Inc., H2 2014 16
Premature Ejaculation - Pipeline by SK Chemicals Co., Ltd., H2 2014 17
Premature Ejaculation - Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2014 18
Premature Ejaculation - Pipeline by Plethora Solutions Holdings plc, H2 2014 19
Premature Ejaculation - Pipeline by NeuroHealing Pharmaceuticals Inc., H2 2014 20
Premature Ejaculation - Pipeline by Furiex Pharmaceuticals, Inc., H2 2014 21
Premature Ejaculation - Pipeline by Dong-A Socio Group, H2 2014 22
Assessment by Monotherapy Products, H2 2014 23
Assessment by Combination Products, H2 2014 24
Number of Products by Stage and Target, H2 2014 26
Number of Products by Stage and Mechanism of Action, H2 2014 28
Number of Products by Stage and Route of Administration, H2 2014 30
Number of Products by Stage and Molecule Type, H2 2014 32
Premature Ejaculation Therapeutics - Recent Pipeline Updates, H2 2014 50
Premature Ejaculation - Dormant Projects, H2 2014 57
Premature Ejaculation - Discontinued Products, H2 2014 58